Ionis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Ionis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Ionis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide. The company was founded in 1989 and is based in Carlsbad, California.
|IONS News: Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia||09/23/2022 02:25:00 AM|
|IONS News: Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing||09/20/2022 08:30:00 AM|
|IONS News: Statement of Changes in Beneficial Ownership (4)||09/12/2022 07:09:52 PM|
|IONS News: Needham Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)||09/07/2022 07:05:42 AM|
|IONS News: Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis||09/07/2022 02:30:00 AM|